Contemporary Oncology (Feb 2024)
Defining the mutational profile of lower-risk myelodysplastic neoplasm patients with respect to disease progression using next-generation sequencing and pyrosequencing
Abstract
No abstracts available.Keywords
Contemporary Oncology (Feb 2024)